EDRE
INSY

Edmond de Rothschild (Europe)’s Insys Therapeutics, Inc. INSY Stock Holding History

Edmond de Rothschild (Europe)’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-750
Closed -$21K – 272
2015
Q4 		$21K Buy
+750
New +$20.8K 0.01% 211

Other funds holding INSY

SCM
Scopia Capital Management New York $112M AUM 48.41% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
GAM
Gotham Asset Management New York $43B AUM 34.97% 1-Year Est. Return
1WCM
12 West Capital Management New York $535M AUM 25.99% 1-Year Est. Return

Edmond de Rothschild (Europe)'s INSY Position: Q1 2016 in Review

Edmond de Rothschild (Europe) sold out of Insys Therapeutics, Inc. (INSY) in Q1 2016, closing a stake of 750 shares — an estimated $21K sold.

Edmond de Rothschild (Europe) first reported a position in INSY in Q4 2015 and held it in 1 quarter. The position peaked at $21K in Q4 2015. 138 funds tracked by Wall St. Rank hold INSY as of Q1 2016.

  • Edmond de Rothschild (Europe) reported no remaining Insys Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
  • Edmond de Rothschild (Europe) sold 750 Insys Therapeutics, Inc. shares in Q1 2016, an estimated $21K.
  • Edmond de Rothschild (Europe) first reported a position in Insys Therapeutics, Inc. in Q4 2015 and held it in 1 quarter.
  • Edmond de Rothschild (Europe)'s Insys Therapeutics, Inc. position peaked at $21K in Q4 2015.
  • 138 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q1 2016.

Based on Edmond de Rothschild (Europe)'s 13F filing for Q1 2016, filed 12 May 2016.